Circulating inflammation-related factors are correlated with systemic redox status in IgA nephropathy; a case-control study

Apeland, Terje; Mansoor, Mohammad Azam; Furriol, Jessica; Ushakova, Anastasia; Jonsson, Grete; Stangeland, Kari Wiig; Marti, Hans-Peter

doi:10.1016/j.freeradbiomed.2020.05.005

Cited by 10 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The buildup of these immune complexes activates the complement system and aggravates neutrophils which further mount an inflammatory response in the vessel wall [ 11 ]. Although IgA nephropathy mainly impacts the vasculature of the kidneys, severe disease can lead to high levels of circulating oxidized free radicals and inflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha, which can cause systemic inflammation [ 12 ]. There are no reported cases of inflammatory-mediated SVCS in patients with IgA nephropathy, however, there are reports of thrombus formation in patients with nephrotic syndromes that lead to SVCS [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

A Rare Case of Superior Vena Cava Syndrome in a Patient With Rheumatoid Arthritis and IgA Nephropathy

Moore¹,

Loichle²,

Tavakolian³

et al. 2022

Cureus

View full text Add to dashboard Cite

Superior vena cava syndrome (SVCS) is a vascular condition resulting from an impaired venous return to the right atrium. The majority of SVCS cases are caused by mass effect in which extrinsic compression of the vessel leads to obstruction of blood flow. In less common cases of SVCS, thrombus formation and luminal narrowing can result in poor return through the SVC. Inflammatory causes of SVCS are even rarer and poorly documented. IgA nephropathy and rheumatoid arthritis (RA) are two autoimmune diseases with the potential to cause vasculitis, thus increasing the likelihood of intraluminal vessel occlusion. We report a rare case of SVCS in a 65-year-old female with a past medical history significant for atrial fibrillation, IgA nephropathy, chronic kidney disease stage IIIA, and RA who presented with headache, dizziness, and neck pain and swelling extending down the left upper extremity for three days. Inflammatory SVCS is uncommon and cases of SVCS secondary to RA and IgA nephropathy are underreported in the literature thus far. Our hope in presenting this case is to encourage a greater degree of suspicion for vascular complications, such as SVCS, in patients with autoimmune and inflammatory conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

A Rare Case of Superior Vena Cava Syndrome in a Patient With Rheumatoid Arthritis and IgA Nephropathy

Moore¹,

Loichle²,

Tavakolian³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Patients Biopsy-proven IgAN patients from West China hospital of Sichuan university between May 2009 and September 2019 were enrolled in this study. The Inclusion criteria were: (1) patients con rmed as IgAN by renal biopsy; (2) patients were followed up for at least 6 months or reached the endpoint of study; (3) patients ≥ 14 years old. The exclusion criteria applied were as follow: (1) patients with systemic disease, such as systemic lupus erythematosus (SLE), Henoch-Schönlein purpura (HSP), liver cirrhosis or disorder of liver function, malignancy etc.…”

Section: Methodsmentioning

confidence: 99%

Lower serum bilirubin is associated with poor renal outcome in IgA nephropathy patients: A retrospective study

Jiang¹,

Tan²,

Wang³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis worldwide. It is meaningful to identify risk factors related to the development of IgAN. We conducted this study to explore the relationship between serum bilirubin and renal outcome of patients with IgAN.Methods: In this retrospective observational study, 1492 biopsy proven IgAN patients were recruited and divided into two groups according to their median baseline serum bilirubin concentration: the low bilirubin group (serum bilirubin≤9.7umol/L, n=753) and high bilirubin group (serum bilirubin>9.7umol/L, n=739). Basic clinical characteristics were assessed at the time of renal biopsy and the relationships between serum bilirubin and the combined endpoints were analyzed. In addition, propensity score matching (PSM) was performed to improve balance and simulate randomization between patients in different groups. Kaplan-Meier survival analysis was applied to explore the role of serum bilirubin in the progression of IgAN. Three models (including demographic, clinical, pathological features and serum bilirubin) of multivariate Cox regression analysis were established to evaluate the association of serum bilirubin and renal prognosis of IgAN.Results: During median 5-year follow-up period, significant differences were shown in Kaplan-Meier analysis. In the unmatched group, 189 (12.7%) patients progressed to the renal combined endpoints. Among this, 122 in 753 patients (16.2%) were in low bilirubin group and 67 in 739 patients (9.1%) were in high bilirubin group (p<0.001). After PSM, there were 134 (11.8%) patients reached the combined endpoints, which included 77 in 566 patients (14.6%) in low bilirubin group and 57 in 566 patients (10.1%) in high bilirubin group (p=0.039). The results of three models (including demographics, pathological, clinical indicators and serum bilirubin) demonstrated that a lower basic serum bilirubin level was significantly associated with a higher risk of reaching combined endpoints in IgAN patients both in unmatched and matched cohort. Conclusion: Serum bilirubin level may be negatively associated with the progression of IgAN.

show abstract

“…Early intervention of these factors may delay the development of IgAN. It is reported that the pathogenesis of IgAN is associated with oxidative stress [2][3][4]. The dynamic balance between oxidation and antioxidation has been destroyed in patients with IgAN [4].…”

Section: Introductionmentioning

confidence: 99%

Lower serum bilirubin is associated with poor renal outcome in IgA nephropathy patients

Jiang¹,

Tan²,

Wang³

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

Aims: IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis worldwide. We conducted this study to explore the relationship between serum bilirubin and renal outcome of patients with IgAN. Methods: A total of 1492 biopsy proven IgAN patients were recruited and divided into two groups according to their median serum bilirubin concentration: the low bilirubin group (serum bilirubin≤9.7umol/L, n=753) and high bilirubin group (serum bilirubin>9.7umol/L, n=739). Basic clinical characteristics were assessed at the time of renal biopsy and the relationships between serum bilirubin and the combined endpoints were analyzed. The combined endpoints were defined as a 50% decline in estimate glomerular filtration rate (e-GFR), end-stage kidney disease (ESKD), renal transplantation and/or death. In addition, propensity score matching (PSM) was then performed to improve balance and simulate randomization between patients in different groups. Kaplan-Meier survival analysis was applied to explore the role of serum bilirubin in the progression of IgAN. Three clinicopathological models of multivariate Cox regression analysis were established to evaluate the association of serum bilirubin and renal prognosis of IgAN. Results: During median 5-year follow-up period, significant differences were shown in Kaplan-Meier analysis. In the unmatched group, 189 (12.7%) patients progressed to the renal combined endpoints. Among this, 122 in 753 patients (16.2%) were in low bilirubin group and 67 in 739 patients (9.1%) were in high bilirubin group (p<0.001). After PSM, there were 134 (11.8%) patients reached the combined endpoints, which included 77 in 566 patients (14.6%) in low bilirubin group and 57 in 566 patients (10.1%) in high bilirubin group (p=0.039). The results of three models (including demographics, pathological, clinical indicators and serum bilirubin) demonstrated that a lower basic serum bilirubin level was significantly associated with a higher risk of reaching combined endpoints in IgAN patients both in unmatched and matched cohort. Conclusion: Serum bilirubin level may be negatively associated with the progression of IgAN.

show abstract

Circulating inflammation-related factors are correlated with systemic redox status in IgA nephropathy; a case-control study

Cited by 10 publications

References 46 publications

A Rare Case of Superior Vena Cava Syndrome in a Patient With Rheumatoid Arthritis and IgA Nephropathy

A Rare Case of Superior Vena Cava Syndrome in a Patient With Rheumatoid Arthritis and IgA Nephropathy

Lower serum bilirubin is associated with poor renal outcome in IgA nephropathy patients: A retrospective study

Lower serum bilirubin is associated with poor renal outcome in IgA nephropathy patients

Contact Info

Product

Resources

About